Cargando…

Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics

Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Meehan, Richard Thomas, Amigues, Isabelle Anne, Knight, Vijaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391624/
https://www.ncbi.nlm.nih.gov/pubmed/34441297
http://dx.doi.org/10.3390/diagnostics11081362
_version_ 1783743318274867200
author Meehan, Richard Thomas
Amigues, Isabelle Anne
Knight, Vijaya
author_facet Meehan, Richard Thomas
Amigues, Isabelle Anne
Knight, Vijaya
author_sort Meehan, Richard Thomas
collection PubMed
description Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics.
format Online
Article
Text
id pubmed-8391624
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83916242021-08-28 Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics Meehan, Richard Thomas Amigues, Isabelle Anne Knight, Vijaya Diagnostics (Basel) Review Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics. MDPI 2021-07-29 /pmc/articles/PMC8391624/ /pubmed/34441297 http://dx.doi.org/10.3390/diagnostics11081362 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Meehan, Richard Thomas
Amigues, Isabelle Anne
Knight, Vijaya
Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title_full Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title_fullStr Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title_full_unstemmed Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title_short Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
title_sort precision medicine for rheumatoid arthritis: the right drug for the right patient—companion diagnostics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391624/
https://www.ncbi.nlm.nih.gov/pubmed/34441297
http://dx.doi.org/10.3390/diagnostics11081362
work_keys_str_mv AT meehanrichardthomas precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics
AT amiguesisabelleanne precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics
AT knightvijaya precisionmedicineforrheumatoidarthritistherightdrugfortherightpatientcompaniondiagnostics